Use of rituximab in NHL malt type pregnant in I° trimester for two times

Use of rituximab in NHL malt type pregnant in I° trimester for two times

Administration of rituximab, one of the basic drugs for the therapy of B-cell lymphoproliferative diseases, during pregnancy has been suspected to cause developmental fetal events, particularly if given during the first trimester of pregnancy. Therefore, use in pregnancy is not permitted. Howe ver,...

Full description

Bibliographic Details
Main Authors: Sica Antonello, Vitiello Paola, Papa Alfonso, Calogero Armando, Sagnelli Caterina, Casale Danilo, Mottola Maria, Svanera Gino, Dodaro Concetta Anna, Martinelli Erika, Troiani Teresa, Ciardiello Fortunato, Casale Beniamino
Format: Article
Language:English
Published: De Gruyter 2019-11-01
Series:Open Medicine
Subjects:
ituximab
pregnancy and rituximab
non-hodgkin lymphoma
Online Access:https://doi.org/10.1515/med-2019-0087

Internet

https://doi.org/10.1515/med-2019-0087

Similar Items